General Catalyst Group Management’s ArriVent BioPharma AVBP Stock Holding History

General Catalyst Group Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.5M	Hold	1,494,786	–	–	18.79%	2
2025 Q4	$30.1M	Hold	1,494,786	–	–	13.56%	5
2025 Q3	$27.6M	Hold	1,494,786	–	–	0.91%	5
2025 Q2	$32.5M	Hold	1,494,786	–	–	0.76%	5
2025 Q1	$27.6M	Hold	1,494,786	–	–	3.11%	6
2024 Q4	$39.8M	Hold	1,494,786	–	–	3.49%	6
2024 Q3	$35.1M	Hold	1,494,786	–	–	2.45%	6
2024 Q2	$27.7M	Hold	1,494,786	–	–	2.39%	5
2024 Q1	$26.7M	Buy	+1,494,786	New	+$30.1M	2.05%	7

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Catalyst Group Management's AVBP Position: Q1 2026 in Review

General Catalyst Group Management held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 1,494,786 shares worth $34.5M. The position accounts for 18.79% of the portfolio, ranked #2.

General Catalyst Group Management first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $39.8M in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

General Catalyst Group Management held 1,494,786 shares of ArriVent BioPharma worth $34.5M as of Q1 2026.
General Catalyst Group Management left its ArriVent BioPharma share count unchanged in Q1 2026.
ArriVent BioPharma made up 18.79% of General Catalyst Group Management's portfolio in Q1 2026, its #2 holding.
General Catalyst Group Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
General Catalyst Group Management's ArriVent BioPharma position peaked at $39.8M in Q4 2024.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on General Catalyst Group Management's 13F filing for Q1 2026, filed 15 May 2026.